First-of-its-Kind Computer-Controlled Robotic Instrument Receives NMPA Certification

DENVER,-- ArcScan, Inc., a global medical technology company dedicated to helping ophthalmologists improve vision with ultra-high frequency ultrasound diagnostic images, announced today that ArcScan Insight® 100 has received National Medical Products Administration (NMPA) approval in China.

“We believe the ArcScan Insight® 100 will help eyecare surgeons in China to better address the myopia epidemic which is predicted to affect 5 billion people globally by 2050 according to the journal Ophthalmology,” stated Andrew Levien, ArcScan CEO. “Surpassing the limitations of optical coherence tomography (OCT), our ultrasound solution provides comprehensive visualization of the anterior segment to help surgeons identify anatomical artifacts that could contribute to substandard post-surgical outcomes.”

Using Insight® 100, eye surgeons can more accurately determine the appropriate sizing of phakic intraocular lenses (pIOL’s) for placement behind the iris for treatment of myopia, commonly known as nearsightedness. According to the 2024 Global IOL Market Report published by Market Scope Reports, the leading market research provider for the eyecare industry, phakic IOL procedures will surpass 780 thousand procedures globally in 2024, with a projected growth rate of 8.8 percent from 2024 to 2029.

“The Insight® 100 has significantly improved outcomes for my patients,” shared Robert Lin, MD, founder and CEO, IQ Laser Vision, California. “The most precise epithelial mapping technology with accuracy down to 1 um allows me to better assess the risk of keratoconus. Better visualization into the anterior segment and reproducible, easy and precise measurement of the sulcus, where the posterior phakic IOL (EVO ICL, Staar and pICL) allows better sizing of the pIOL to reduce potential risks of lens rotation, glaucoma and cataracts.”